Related Experiment Video
Updated: Dec 18, 2025
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
Galactosylated TPGS Micelles for Docetaxel Targeting to Hepatic Carcinoma: Development, Characterization, and
Pawan Tekchandani1, Balak Das Kurmi1, Rishi Paliwal2
1Pharmaceutics Research Laboratory, SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur, 495 009, India.
Abstract:
Hepatocellular carcinoma (HCC) is a foremost type of cancer problem in which asialoglycoprotein receptors are overexpressed. In this study, asialoglycoprotein receptor-targeted nanoformulation (galactose-conjugated TPGS micelles) loaded with docetaxel (DTX) was developed to achieve its site-specific delivery for HCC therapy. The pharmaceutical characteristics like shape morphology, average particle size and zeta potential, drug entrapment efficiency, and in vitro release kinetics of developed system were evaluated. DTX-loaded galactosylated TPGS (DTX-TPGS-Gal) micelles and TPGS micelles (DTX-TPGS) were having 58.76 ± 1.82% and 54.76 ± 1.42% entrapment of the DTX, respectively. In vitro drug release behavior from micelles was controlled release. Cytotoxicitiy (IC50) of DTX-TPGS-Gal formulation on HepG2 cell lines was significantly (p ≤ 0.01) lower (6.3 ± 0.86 μg/ml) than DTX-TPGS (9.06 ± 0.82 μg/ml) and plain DTX (16.06 ± 0.98 μg/ml) indicating higher efficacy of targeted formulation. Further, in vivo biodistribution studies in animal model showed maximum drug accumulation at target site, i.e., the liver in the case of DTX-TPGS-Gal as compared with non-targeted one. It is concluded from the findings that TPGS-Gal micelles can be utilized for targeted drug delivery of cytotoxic drugs towards HCC with minimized side effects. Graphical abstract.
Insights
Targeted nanoformulation using galactose-conjugated TPGS micelles delivers docetaxel effectively for hepatocellular carcinoma (HCC) therapy. This approach enhances drug accumulation at the liver tumor site, showing improved efficacy and reduced side effects compared to non-targeted methods.
Area of Science:
- Nanotechnology
- Oncology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) overexpresses asialoglycoprotein receptors.
- Targeted drug delivery systems are crucial for enhancing therapeutic efficacy in HCC.
- Docetaxel (DTX) is a chemotherapeutic agent with potential for HCC treatment.
Purpose of the Study:
- To develop and evaluate a novel asialoglycoprotein receptor-targeted nanoformulation for site-specific delivery of docetaxel (DTX) in HCC therapy.
- To investigate the pharmaceutical characteristics and in vitro/in vivo performance of the targeted nanoformulation.
- To assess the efficacy and biodistribution of the targeted nanoformulation in HCC models.
Main Methods:
- Development of galactose-conjugated TPGS micelles loaded with docetaxel (DTX-TPGS-Gal).
- Evaluation of pharmaceutical characteristics: morphology, particle size, zeta potential, drug entrapment efficiency, and in vitro release kinetics.
- Assessment of in vitro cytotoxicity on HepG2 cell lines and in vivo biodistribution studies in an animal model.
Main Results:
- DTX-TPGS-Gal micelles demonstrated high drug entrapment efficiency (58.76%).
- In vitro studies showed controlled drug release and significantly lower IC50 values for DTX-TPGS-Gal compared to non-targeted formulations and plain DTX.
- In vivo biodistribution studies confirmed maximum drug accumulation in the liver (target site) for the DTX-TPGS-Gal formulation.
Conclusions:
- TPGS-Gal micelles are effective for targeted drug delivery of cytotoxic agents to HCC.
- The developed nanoformulation shows enhanced efficacy and potential for minimizing side effects in HCC treatment.
- This targeted approach holds promise for improving the therapeutic outcomes in hepatocellular carcinoma.
